1. Introduction {#s0005}
===============

Phenylalanine hydroxylase (PAH) deficiency, often referred to as Phenylketonuria (PKU) (OMIM \#[261600](261600){#ir0005}) is the most common inborn error of protein metabolism, affecting approximately 1/10,000 people of Northern European or East Asian descent \[[@bb0005]\]. The enzyme deficiency leads to a decreased conversion of phenylalanine (Phe) to tyrosine. Without treatment to reduce Phe levels, an individual with PAH deficiency can develop intellectual disability, seizures, and autism-like features. The mainstay of treatment is diet restriction to reduce Phe intake and medical formula to supply adequate protein. Identification most commonly occurs on newborn screen with an elevation in Phe on dried blood specimens.

In the Plain Community, including Amish and Mennonite populations, there is an increased frequency of genetic disorders due to founder effect and closed community. Several metabolic disorders, including PAH deficiency, are more common in the Plain Community compared with the general population. The exact incidence in the Plain Community is unknown, but it is estimated at 1/1000 people \[[@bb0010]\]. There are four reported common pathogenic variants in PAH identified in the Amish and Mennonite populations in Pennsylvania and Ohio: 284_286delTCA, c.782G \> A, IVS10-11G \> A, and IVS12 + 1G \> A, but no allelic frequency for each pathogenic variant is not known \[[@bb0010],[@bb0015]\]. These PAH pathogenic variants are also described in the general population \[[@bb0020], [@bb0025], [@bb0030]\].

In Wisconsin, the 2017 Amish population is estimated at 20,095 and is derived from Amish from both Pennsylvania and Ohio \[[@bb0035]\]. Improved newborn screening rates within this population have allowed for early diagnosis and treatment of Amish individuals with PAH deficiency in Wisconsin. Increased knowledge of common genotypes in the Wisconsin community will help aid in diagnosis and management \[[@bb0040]\].

2. Materials and methods {#s0010}
========================

The study was open to Plain community patients with PAH deficiency who are receiving care at the University of Wisconsin (UW) metabolic clinic. This study was approved by the UW Institutional Review Board. After appropriate consent, targeted Sanger sequencing was performed for the common Plain community pathogenic variants PAH 284_286delTCA (p.I94del), PAH c.782G \> A (p.R261Q), PAH IVS10-11G \> A, and PAH IVS12 + 1G \> A). If 2 common pathogenic variants were not found, PAH gene was sequenced for other disease-causing pathogenic variants. Reference sequence NM_000277.2(PAH) was used for PAH for PAH valiant annotation.

A chart review of each patient was completed for Phe levels and estimated Phe tolerance. For individuals diagnosed in the neonatal period (Cases 1--7), a combination of breastmilk/standard infant formula and medical formula was initiated after abnormal newborn screen. The amount of medical formula was titrated based on frequent Phe levels (weekly to twice weekly depending on age). Phe tolerance was estimated based on approximate daily intake of breastmilk or standard infant formula. For cases 8--12 where clinical diagnosis occurred, all patients were on a casein free/gluten free diet to improve behavioral concerns at time of diagnosis. For these late diagnosed individuals, initiation of Phe restricted diet was done in a stepwise fashion (formula first, then gradual restriction of whole protein).

Currently all individuals are on the simplified PKU diet counting grams of protein instead of milligrams of Phe. Fruits and vegetables with less than 0.75 mg Phe per gram are considered free and do not need to be counted. Daily Phe tolerance is estimated from the protein goal (50 mg Phe per 1 g protein) plus assumed 100 mg Phe from uncounted fruits and veggies. With Amish patients, there is limited communication with families which may impact estimation.

3. Results {#s0015}
==========

Twelve patients were identified and participated in this study. Results are summarized in [Table 1](#t0005){ref-type="table"}. Presentations included detection by newborn screen without family history of PAH deficiency, newborn screen with family history, and clinical diagnosis. Diagnosis was based on dried blood spot Phe levels of greater than 2.5 mg/dl in the newborn period or greater than 1.5 mg/dl outside the newborn period. Cases 1--7 were diagnosed by newborn screening with Cases 2, 6, and 7 a family history was known. The 7 patients identified by newborn screen and/or family history in the newborn period demonstrate normal growth and development. Clinical diagnosis of PAH deficiency was initially suspected in Case 12 due to intellectual disability, seizures, autism, decrease pigmentation, and a history of no newborn screen. All symptomatic siblings had moderate to severe intellectual disability and autistic like behaviors. Due to cultural norms, none have undergone formal evaluation for IQ or formal diagnosis of autism. Subsequent testing of the four older siblings (Cases 8--11) was completed due to their similar features, confirming diagnoses of PAH deficiency.Table 1Clinical, genotypic, phenotypic information on Amish individuals with phenylalanine hydroxylase deficiency in Wisconsin.Table 1CasePresentationFamily state of originPhe on NBS (mg/dl)Age at NBSAverage Phe level (mg/dl)Estimated average Phe tolerance (mg/day)Current estimated Phe tolerance (mg/day)GenotypePhenotype0--6 months6--12 months0--6 months6--12 monthsMutation 1Mutation 21Newborn screen^a^NA15.86 days4.93.6257233At 8 years old, 250--300 mgc.1066-11G \> Ac.1066-11G \> AClassical2Family history^a^NA5.05 days4.02.1196180At 4 years old, 250--300 mgc.1066-11G \> Ac.1066-11G \> AClassical3Newborn screenIN/VA1819 days4.04333462At 5 years old, 300--325 mgc.1066-11G \> Ac.168 + 5G \> CClassical4Newborn screenPA/PA3.248 h2.52.4419868At 4 years old, 1550 mgc.284_286delTCAc.284_286delTCAMild5Newborn screen^b^OH/IN7.873 h4.83.2191218At 5 years old, 300--350 mgc.1066-11G \> Ac.1066-11G \> AClassical6Family history^b^OH/IN5.325 h3.54.7172194At 4 years old, 300--350 mgc.1066-11G \> Ac.1066-11G \> AClassical7Family history^b^OH/IN7.639 h3.5NA^1^208NA^1^At 20 months old, 350 mg PHEc.1066-11G \> Ac.1066-11G \> AClassical  Phe at diagnosis (mg/dl)Age at diagnosis8Clinical presentation^c^16.320 yearsNANANANAAt 21 years old, 300--400 mgc.1066-11G \> Ac.1066-11G \> AModerate - Classical9Clinical presentation^a^12.919 yearsNANANANAAt 20 years old, 300--400 mgc.1066-11G \> Ac.1066-11G \> AModerate - Classical10Clinical presentation^c^15.318 yearsNANANANAat 19 years old, 300--400 mgc.1066-11G \> Ac.1066-11G \> AModerate - Classical11Clinical presentation^c^14.011 yearsNANANANAat 12 years old, 300--400 mgc.1066-11G \> Ac.1066-11G \> AModerate - Classical12Clinical presentation^c^15.79 yearsNANANANAat 10 years old, 300--400 mgc.1066-11G \> Ac.1066-11G \> AModerate - Classical[^1][^2][^3]

For Cases 1--7, all infant average Phe levels were within the treatment range of 2--6 mg/dl. Variable Phe tolerances were observed between patients, but most patients were relatively consistent over time with the exception of cases 3 and 4 whose Phe tolerance increased 28% and 52%, respectively, during the first year of life. No patient has been trialed on saproterin.

For Cases 8--12, most recent Phe levels in all five patients were below 6 mg/dl. Parents have not provided diet records, but dietary recommendations and verbal report implies these patients would fit with a classical phenotype.

Genotype was completed on all twelve individuals. All but one allele (Case 3) had pathogenic variants identified that were of the 4 pathogenic variants common in the Plain community. Sequencing of the PAH gene in Case 3 showed a previously described pathogenic variant \[[@bb0045],[@bb0050],[@bb0055]\].

For phenotype classification, current dietary Phe tolerance was used to subdivide to classic, moderate, mild and mild hyperphenylalaninemia \[[@bb0060]\]. All cases but case \#4 were moderate to classical. For case \#4, estimated Phe would place the individual as benign, but he requires treatment to maintain levels less than 6 mg/dl. Therefore, he was categorized as mild PAH deficiency.

4. Discussion {#s0020}
=============

PAH deficiency appears to be more common in the Plain community as estimated in Ohio at 1/1000 people. In Wisconsin, with an estimated Amish population of 20,000, 14 individuals with PAH deficiency are followed, many are school aged or younger. There are challenges to treatment in this population and increased knowledge of the genotype and its corresponding phenotype can help with diagnosis as well as management.

Frequently, the identification of PAH deficiency is made by newborn screen. In a community where cost is a large factor in follow-up of healthcare, the use of genotype could allow for molecular confirmation of PAH deficiency diagnosis in a more time- and cost-efficient manner. In the setting of a newborn screen, common pathogenic variants testing could be completed at the newborn screen lab when an elevated Phe is detected in a patient that is identified as part of the Plain community. Two identified disease-causing pathogenic variants would confirm diagnosis, eliminating the need for biopterin studies, saving patient cost and allowing for more timely diagnosis. If two pathogenic variants are not identified, then biopterin testing would be required.

The genotypes of Wisconsin Amish patients included two mutations commonly found in the Plain community: c.1066-11G \> A and 284_286delTCA. 284_286delTCA has a reported biochemical phenotype of less elevated Phe levels over the first year of life with increasing levels after this time (personal communication -- Dr. Holmes Morton 6/11/16). Case 4's (homozygous for this genotype) initial biochemical phenotype fit with hyper-phe and treatment was not required to maintain Phe levels in the treatment range (2--6 mg/dl) during the first year of life. With age, Phe tolerance declined and formula was initiated between 12 and 18 months to maintain Phe levels in the treatment range. Currently, Case 4 is on the simplified PKU diet, receives 25 g whole protein/day, and does not demonstrate a classical presentation. Knowledge of this milder phenotype would help avoid false assumption of benign hyper-phe particularly in a community where follow-up to medical care can be challenging. Medical formula can be initiated during the first year to avoid later formula intolerance. This mutation, with its milder phenotype and presumed residual enzyme activity, would likely also be responsive to sapropterin \[[@bb0065]\].

The pathogenic variant, c.1066-11G \> A, is associated with a classical PAH deficiency phenotype \[[@bb0065]\]. This more severe biochemical phenotype was demonstrated in all homozygous patients. Case 1 did appear to have a high tolerance in the first few months of life, possibly related to history of prematurity necessitating catch-up growth (increase Phe need), and breastfeeding (there is less Phe per ounce of breast milk than standard infant formula). In the literature, this genotype is not responsive to sapropterin \[[@bb0065]\]. The third pathogenic variants, a splice site pathogenic variants c.168 + 5G \> C, found in Case 3 has not been previously described in the Plain community. It was initially described in German and Polish individuals with PAH deficiency, where the Plain community originates, but has been reported in other populations as well. While this pathogenic variants c.168 + 5G \> C, is predicted to cause a classical PAH deficiency phenotype, there are reports of the pathogenic variants in combination with other mutations (p.Glu178Gly or pArg395Gly) presenting as hyper-phe or mild PAH deficiency \[[@bb0050],[@bb0055],[@bb0070]\]. One report showed 50% of patients with this pathogenic variants responded to saproterin although it is unclear if patients were homozygotes for the pathogenic variant or compound heterozygotes \[[@bb0075]\]. Case 3 is a compound heterozygote for the c.1066-11A \> G pathogenic variant (classical pathogenic variant) and this pathogenic variant. Phe tolerance is approximately twice that of those homozygous for the c.1066-11A \> G pathogenic variant.

This study is limited by its small size. Further study of the genotype and phenotype in the Plain community are needed to verify our observation and to see if other genotypes exist in this closed community. The genotype would aid in diagnosis and also help the clinician predict phenotype and expectations for level of intervention needed for adequate treatment and possible sapropterin responsiveness.

[^1]: N/A -- Not available 1. Below 1 year of age at the time of data collection.

[^2]: States -- IN -- Indiana, OH -- Ohio, PA -- Pennsylvania, VA -- Virginia.

[^3]: Sibships -- a. Family \#1 b. Family \#2 c. Family \#3.
